In a patient with heart failure with preserved ejection fraction and stage 3b chronic kidney disease using a bilevel positive airway pressure device, can isolated periods of 5–10 central apneas over a 30‑minute interval be harmful despite an overall nightly apnea‑hypopnea index below 5?

Yes, Isolated Clusters of Central Apneas Can Be Harmful in HFpEF with CKD Despite Low Overall AHI

Even with an overall AHI below 5, isolated periods of 5-10 central apneas clustered over 30 minutes each night warrant intervention in your patient with HFpEF and stage 3b CKD, as these events can trigger acute hemodynamic stress, sympathetic surges, and hypoxic burden that compound cardiovascular and renal risk.

Why Clustered Central Apneas Matter Despite Low Overall AHI

The 2025 AASM guidelines explicitly state that clinicians must prioritize optimizing therapy for conditions contributing to central apneas and improving patient-reported outcomes rather than solely focusing on eliminating disordered breathing events 1. This is critical because:

• Clustered apneas create acute physiological stress: Even brief periods of repetitive central apneas cause cyclic hypoxemia, sympathetic activation, blood pressure surges, and increased cardiac afterload—all particularly damaging in HFpEF where diastolic dysfunction and ventricular stiffness are already compromised 2
• HFpEF patients are uniquely vulnerable: Your patient has impaired ventricular filling, myocardial fibrosis, and endothelial dysfunction that make them less tolerant of even intermittent respiratory events 3, 4, 5
• CKD amplifies risk: Stage 3b CKD creates bidirectional cardiorenal pathophysiology with systemic inflammation and neurohormonal activation that worsens with hypoxic stress 3, 4

Research demonstrates that unsuppressed sleep apnea in heart failure patients—even at lower overall AHI levels—is associated with worse prognosis, including higher hospitalization and mortality rates 6.

Your Current Bilevel Setup Is Likely Inadequate

The 2025 AASM guidelines suggest against bilevel PAP without a backup rate for CSA in heart failure 1. If your patient's bilevel machine lacks a backup rate (timed breaths), this explains the persistent central apneas:

• Without backup rate: The machine cannot prevent central apneas—it only responds after they occur
• With backup rate: The device delivers mandatory breaths during apneic periods, preventing the clustered events you're observing

Recommended Action Algorithm

Step 1: Verify Device Settings

• Confirm whether the current bilevel machine has a backup rate (respiratory rate) enabled
• If no backup rate exists, the device is functioning as simple bilevel PAP, which is insufficient for CSA 1

Step 2: Optimize PAP Therapy Based on Device Capability

If backup rate is available but not activated:

• Enable backup rate at 12-15 breaths/minute (typically 2-3 breaths below patient's spontaneous rate)
• This converts the therapy to bilevel PAP with backup rate, which the AASM conditionally recommends for CSA 1

If device lacks backup rate capability:

• Consider upgrading to adaptive servo-ventilation (ASV), which the AASM suggests for CSA in HFpEF 1, 7
• Critical caveat: ASV is safe in HFpEF (preserved ejection fraction) but requires shared decision-making and should focus on symptomatic/quality-of-life improvement 1, 7
• ASV effectively normalizes central apneas by dynamically adjusting pressure support 8, 9

Alternative if ASV unavailable:

• Trial supplemental oxygen (1-3 L/min nocturnal oxygen), which the AASM suggests for CSA in heart failure 1
• Oxygen reduces ventilatory instability and can suppress central apneas 9

Step 3: Re-evaluate Underlying Contributors

The 2025 AASM guidelines emphasize that persistence of central events should prompt re-evaluation of underlying risk factors 1:

• Optimize heart failure management: Ensure guideline-directed medical therapy for HFpEF (SGLT2 inhibitors show strongest evidence) 3, 4, 5
• Assess volume status: Fluid overload worsens CSA in heart failure 10
• Review medications: Opioids, benzodiazepines, and other CNS depressants can trigger central apneas 1
• Check for anemia: Iron deficiency anemia exacerbates CSA in cardiac patients 11

Step 4: Monitor Response

After intervention, repeat sleep study in 1-3 months to confirm:

• Reduction in clustered central apnea events
• Improved oxygen saturation patterns
• Patient-reported symptom improvement (fatigue, daytime sleepiness, sleep quality)

Common Pitfalls to Avoid

1. Don't dismiss low overall AHI: The distribution and clustering of events matters as much as the total number 6
2. Don't use bilevel without backup rate for CSA: This is explicitly not recommended 1
3. Don't ignore patient symptoms: Even if numbers seem acceptable, persistent fatigue, dyspnea, or poor sleep quality indicate inadequate control 1
4. Don't use ASV algorithms designed for HFrEF: Older ASV devices with fixed minimum pressure support may not be optimal; newer variable algorithms are preferred 7

Evidence Quality Considerations

The 2025 AASM guidelines provide conditional recommendations with low-to-very-low certainty evidence for most CSA treatments 1. However, the consistent finding across multiple studies is that unsuppressed sleep apnea in heart failure predicts worse outcomes 6, 10, 9. The European Respiratory Society 2025 statement confirms that specific phenotypes (including HFpEF) show benefit from ASV therapy when individualized appropriately 7.

Given your patient's high-risk profile (HFpEF + stage 3b CKD), erring on the side of more aggressive CSA treatment is justified to prevent cardiovascular decompensation and CKD progression.